Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
- To determine the effect of a single dose of Herceptin (trastuzumab) on the proliferation
rate of Her-2/neu over-expressing ductal carcinoma in situ (DCIS)
- To evaluate the effect of a single dose of Herceptin on the apoptotic index of Her-2/neu
over-expressing DCIS